Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01776567
Registration number
NCT01776567
Ethics application status
Date submitted
11/08/2012
Date registered
28/01/2013
Date last updated
5/08/2014
Titles & IDs
Public title
Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms
Query!
Scientific title
Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms.
Query!
Secondary ID [1]
0
0
01/12
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
APPOSE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Active comparator: Cobalt Chromium Everolimus-eluting stent (Xience Prime) - Cobalt Chromium Everolimus-eluting stent (Xience Prime)
Active comparator: Platinum Chromium Everolimus-eluting stent (Promus Element) - Platinum Chromium Everolimus-eluting stent (Promus Element)
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
• Percent incomplete stent apposition using OCT of the CoCr-EES versus the PtCr-EES stent inflated to nominal pressure and following optimal post-dilatation. Stent length (mm) at implantation following nominal pressure and following post-dilatation
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Immediately following stent deployment
Query!
Secondary outcome [1]
0
0
Percentage of uncovered stent struts
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
6 mths post initial PCI procedure
Query!
Secondary outcome [2]
0
0
Mean neointimal tissue thickness (microns)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
6 months post initial PCI Procedure
Query!
Secondary outcome [3]
0
0
Stent length (mm) measured using OCT
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
6 months post initial PCI procedure
Query!
Eligibility
Key inclusion criteria
1. Age = 18 years
2. Symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes including non-ST elevation myocardial infarction
3. Presence of one or more coronary artery stenosis > 50% in a native coronary artery with a reference diameter ranging from 2.25 to 4.25 mm which can be covered with one or multiple stents
4. No limitation to the number of treated lesions or number of vessels according to the randomization group
5. De-novo native coronary disease with complex lesions involving: Bifurcations, chronic occlusions > 3 months, lesions > 20mm in length or moderately/heavily calcified lesions of any length
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Known intolerance to aspirin, clopidogrel, heparin, cobalt chromium, platinum chromium, everolimus, contrast material
2. Acute ST-segment elevation myocardial infarction
3. Type A lesion including vessel angulation <45 degrees
4. Bypass graft
5. Inability to provide informed consent
6. Pregnancy
7. Planned surgery within 12 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period
8. Left ventricular ejection fraction < 25%
9. Serum creatinine > 180mmol/L
Query!
Study design
Purpose of the study
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
UNKNOWN
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2015
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Concord Repatriation Hospital - Concord
Query!
Recruitment hospital [2]
0
0
The Prince Charles Hospital - Brisbane
Query!
Recruitment hospital [3]
0
0
Northern Hospital - Epping
Query!
Recruitment hospital [4]
0
0
St Vincent's Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Concord
Query!
Recruitment postcode(s) [2]
0
0
- Brisbane
Query!
Recruitment postcode(s) [3]
0
0
3076 - Epping
Query!
Recruitment postcode(s) [4]
0
0
3065 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Northern Hospital, Australia
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Abbott Medical Devices
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the trial is to directly compare the Cobalt Chromium platform everolimus-eluting stent, Xience Prime™, with the Platinum Chromium platform everolimus-eluting stent, Promus Element™, in relation to stent scaffolding shape, position with the heart blood vessel and extent of tissue coverage (at 6 months) using optical coherence tomography. Hypotheses: 1. The alloy composition and strut design of a drug-eluting stent has a direct bearing on stent apposition measured using OCT. 2. Stent design and alloy composition have a direct influence on radial support and scaffold shrinkage.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01776567
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Peter Barlis
Query!
Address
0
0
Northern Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Peter Barlis, MBBS MPH PHD FESC FRACP
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61 3 8405 8554
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01776567
Download to PDF